Navidea Biopharmaceuticals. has filed a patent for compounds and methods to repolarize tumor-associated macrophages, reduce inflammation, and treat diseases like cancer, autoimmune disorders, and infections. The compound includes a polymeric carbohydrate backbone, targeting moieties, and a therapeutic agent linked via a degradable linker. GlobalData’s report on Navidea Biopharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Navidea Biopharmaceuticals, Isotropically modified heterocyclic compounds was a key innovation area identified from patents. Navidea Biopharmaceuticals's grant share as of January 2024 was 44%. Grant share is based on the ratio of number of grants to total number of patents.
Polymeric compound for treating diseases involving macrophages
The patent application (Publication Number: US20240024491A1) describes a compound designed for targeted drug delivery. The compound consists of a polymeric carbohydrate backbone, mannose-binding C-type lectin receptor targeting moieties, and a therapeutic agent with reactive hydroxyl groups linked via a degradable linker. The compound can include various components such as mannosyl coupling reagents, glycans, and peptides to target specific receptors. Additionally, the therapeutic agent can be a corticosteroid, chemotherapeutic agent, or toll-like receptor agonist/antagonist, among others. The compound can be used in pharmaceutical compositions with a carrier for effective delivery.
Furthermore, the patent application details methods for making and using the compound. The synthesis involves attaching leashes to the carbohydrate backbone, forming a therapeutic-linker compound, and conjugating it to the backbone. The compound can be administered to repolarize tumor-associated macrophages, reduce inflammation mediated by macrophages, or treat various diseases like cancer, autoimmune disorders, and inflammatory conditions. The therapeutic agent's release can be triggered by a reducing agent, making it suitable for conditions like Non-Alcoholic Steatohepatitis (NASH), acute respiratory distress syndrome (ARDS), sepsis, and viral infections. The compound can be used alone or in combination with other therapies such as chemotherapy, radiation therapy, or immunotherapy for enhanced treatment outcomes.
To know more about GlobalData’s detailed insights on Navidea Biopharmaceuticals, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
